Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence

• GOUREVITCH MN, FRIEDLAND GH: Interactions between methadone and medications used to treat HIV infection: a review. Mt. Sinai J. Med. (2000) 67(5-6):429-436.
   PubMed Web of Science ®Google Scholar
• FARAGON JJ, PILIERO PJ: Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Read. (2003) 13(9):433-434, 437-441, 446-450.
   PubMedGoogle Scholar
• UNAIDS: 2004 Report on the global AIDS epidemic. UNAIDS (2004).
   Google Scholar
• KERR T, WODAK A, ELLIOTT R, MONTANER JS, WOOD E: Opioid substitution and HIV/AIDS treatment and prevention. Lancet (2004) 364(9449):1918-1919.
   PubMed Web of Science ®Google Scholar
• GIBSON DR, FLYNN NM, PERALES D: Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS (2001) 15(11):1329-1341.
   PubMed Web of Science ®Google Scholar
• STRATHDEE SA, PALEPU A, CORNELISSE PG etal.: Barriers to use of free antiretroviral therapy in injection drug users. JAMA (1998) 280(6):547-549.
   PubMed Web of Science ®Google Scholar
• FARRE M, MAS A, TORRENS M, MORENO V, CAMI J: Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend. (2002) 65(3):283-290.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION UNOODAC, UNAIDS: Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: position paper (2004).
   Google Scholar
• WOOD E, MONTANER JS, BANGSBERG DR etal.: Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS (2003) 17(17):2419-2427.
   PubMed Web of Science ®Google Scholar
• ANTELA A, CASADO JL, GONZALEZMJ etal.: Influence of a methadone maintenance programme on the improved outcome of a cohort on injecting drug users with advanced HIV disease. AIDS (1997) 11(11):1405-1406.
   PubMed Web of Science ®Google Scholar
• CAPLEHORN JR, ROSS MW: Methadone maintenance and the likelihood of risky needle-sharing. Int. J. Addict. (1995) 30(6):685-698.
   PubMed Web of Science ®Google Scholar
• CAPLEHORN JR, DALTON MS, HALDAR F, PETRENAS AM, NISBETJG: Methadone maintenance and addicts risk of fatal heroin overdose. Subst. Use Misuse (1996) 31(2):177-196.
   PubMed Web of Science ®Google Scholar
• MOATTI JP, CARRIERI MP, SPIRE B etal.: Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS (2000) 14(2):151-155.
   PubMed Web of Science ®Google Scholar
• ADDICTION NCDPOEMTOO: Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA (1998) 280(22):1936-1943.
   PubMed Web of Science ®Google Scholar
• HOGG RS, YIP B, KULLY C etal.: Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ (1999) 160(5):659-665.
   PubMed Web of Science ®Google Scholar
• HAMMER SM, SQUIRES KE, HUGHESMD etal.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. (1997) 337(11):725-733.
   PubMed Web of Science ®Google Scholar
• CARPENTER CC, COOPER DA, FISCHL MA etal.: Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 283(3):381-390.
   PubMed Web of Science ®Google Scholar
• WOOD E, MONTANER JS, YIP B etal.: Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 169(7):656-661.
   PubMed Web of Science ®Google Scholar
• BANGSBERG DR, HECHT FM, CHARLEBOIS ED etal.: Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 14(4):357-366.
   PubMed Web of Science ®Google Scholar
• KERR T, PALEPU A, BARNESS G etal.: Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antivir. Ther. (2004) 9(3):407-414.
   PubMed Web of Science ®Google Scholar
• PALEPU A, HORTON NJ, TIBBETTS N, MELI S, SAMET JH: Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction (2004) 99(3):361-368.
   PubMed Web of Science ®Google Scholar
• RAINEY P: HIV drug interactions: the good, the bad, and the other. Ther. Drug Monit. (2002) 24(1):26-31.
   PubMed Web of Science ®Google Scholar
• HANSTEN PD: Drug Interactions. In: Applied Therapeutics: Clinical Use of Drugs (6th edn). MA Koda-Kimble, LY Young (Eds), Applied Therapeutics, Inc., Vancouver, WA, USA (1995).
   Google Scholar
• FERRARI A CC, BERTOLINI A, STERNIERI E: Methadone metabolism, pharmacokinetics and interactions. Pharmacol. Res. (2004) 50(6):551-559.
   PubMed Web of Science ®Google Scholar
• HARDMAN JG LL, GILMAN AG: Goodman & Gilmanss The Pharmacological Basis of Therapeutics. McGraw-Hill Professional, New York, USA (2001).
   Google Scholar
• SCHWARTZ EL BA, KAHL P, MILLERMA, SELWYN PA, FRIEDLAND GH: Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J. Acquir. Immune Defic. Syndr. (1992) 5(6):619-626.
   PubMed Web of Science ®Google Scholar
• MCCANCE-KATZ EF, RAINEY PM, JATLOW P, FRIEDLAND G: Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J. Acquir. Immune Defic. Syndr. (1998) 18(5):435-443.
   Web of Science ®Google Scholar
• MCCANCE-KATZ EF, RAINEY PM, FRIEDLAND G, KOSTEN TR, JATLOWP: Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am. J. Addict. (2001) 10(4):296-307.
   PubMed Web of Science ®Google Scholar
• RAINEY PM FG, SNIDOW JW, MCCANCE-KATZ EF etal.: The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am. J. Addict. (2002) 11(1):66-74.
   PubMed Web of Science ®Google Scholar
• RAINEY PM, FRIEDLAND G, MCCANCE-KATZ EF et al.: Interaction of methadone with didanosine and stavudine. J. Acquir. Immune Defic. Syndr. (2000) 24(3):241-248.
   PubMed Web of Science ®Google Scholar
• FRIEDLAND G, RAINEY PM, JATLOWP etal.: Pharmacokinetics (pK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) versus chewable tablet formulation (EC) in patients (pts) on chronic methadone therapy. In: Program and abstracts of the XIV International AIDS Conference. Barcelona, Spain (2002). Abstract TuPeB4548.
   Google Scholar
• SELLERS E, LAM R, MCDOWELL J, ALE: The pharmacokinetics (PK) of abacavir (ABC) and methadone (M) following coadministration: CNAA1012. In: Program and abstracts of the 39th Interscience Cionfer-on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999). Abstract 663.
   Google Scholar
• SMITH P, KEARNEY B, CLOEN D etal.: Tenofovir DF does not affect the pharmacokinetics or pharmacodynamics of methadone. In: Program and abstracts of the 2nd International AIDSSociety Conference on HIV Pathogenesis and Treatment. Paris, France (2003) Abstract 869.
   Google Scholar
• CLARKE SM, MULCAHY FM, TJIA J etal.: Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin. Infect. Dis. (2001) 33(9):1595-1597.
   PubMed Web of Science ®Google Scholar
• STOCKER H, KRUSE G, KRECKEL P etal.: Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human inmmunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2004) 48:4148-4153.
   PubMed Web of Science ®Google Scholar
• HEELON MW, MEADE LB: Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy (1999) 19:471-472.
   PubMed Web of Science ®Google Scholar
• ALTICE FL, FRIEDLAND GH, COONEY EL: Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS (1999) 13(8):957-962.
   PubMed Web of Science ®Google Scholar
• OTERO MJ, FUERTES A, SANCHEZ R, LUNA G: Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert [letter]. AIDS (1999) 13(8):1004-1005.
   PubMed Web of Science ®Google Scholar
• STASZEWSKI S, HARBERL A, GUTE P, NISIUS G, MILER V, CARLEBACH A: Nevirapine/didanosine/lamivudine once daily in HIV-1 infected intravenous drug users. Antivir. Ther. (1998) 3:55-56.
   PubMed Web of Science ®Google Scholar
• CLARKE SM, MULCAHY FM, TJIA J etal.: The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. (2001) 51(3):213-217.
   PubMed Web of Science ®Google Scholar
• MARZOLINI C, TROILLET N, TELENTI A etal.: Efavirenz decreases methadone blood concentrations. AIDS (2000) 14:1291-1292.
   PubMed Web of Science ®Google Scholar
• BOFFITO M, ROSSATI A, DAL CONTE I etal.: Opiate withdrawal syndrome in new efavirenz recipients under methadone maintenance regimen. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Brazil (2001).
   Google Scholar
• PINZANI V, FAUCHERRE V, PEYRIEREH, BLAYAC JP: Methadone withdrawal symptoms with nevirapine and efavirenz. Ann. Pharmacother. (2000) 34(3):405-407.
   PubMed Web of Science ®Google Scholar
• MCCANCE-KATZ EF, RAINEY P, SMITH P etal.: Drug interactions between opioids and antiretriviral medications: interaction between methadone, LAAM, and delavirdine. Am. J. Addict. (2006) 15(1):23-34.
   PubMed Web of Science ®Google Scholar
• BOOKER B, SMITH P, FORREST A etal.: Lack of effect of methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) & N-delavirdine [abstract A 490]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001):14.
   Google Scholar
• MOYLE GJ, BACK D: Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. (2001) 2(2):105-113.
   PubMedGoogle Scholar
• IRIBARNE C, BERTHOU F, CARLHANT D et al.: Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab. Dispos. (1998) 26(3):257-260.
   PubMed Web of Science ®Google Scholar
• HSU A, GRANNEMAN GR, CAROTHERS L et al.: Ritonavir does not increase methadone exposure in healthy volunteers. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (1998). Abstract 342.
   Google Scholar
• GELETKO SM, ERICKSON AD: Decreased methadone effect after ritonavir initiation. Pharmacotherapy (2000) 20(1):93-94.
   PubMed Web of Science ®Google Scholar
• MCCANCE-KATZ EF, RAINEY P, FRIEDLAND G, JATLOW P: The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin. Infect. Dis. (2003) 37(4):476-482.
   PubMed Web of Science ®Google Scholar
• GERBER JG, ROSENKRANZ S, SEGALY etal.; ACTG 401 STUDY TEAM: Effect of ritonavir/saquinavir on stereoselective phamaco kinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J. Acquir. Immune Defic. Syndr. (2001) 27:153-160.
   PubMed Web of Science ®Google Scholar
• SHELTON MJ, CLOEN D, DIFRANCEXCO R etal.: The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J. Clin. Pharmacol. (2004) 44(3):293-304.
   PubMed Web of Science ®Google Scholar
• SHELTON MJ, CLOEN D etal.: Pharmacokinetics (PK) of once daily (QD) saquinavir/ritonavir (SQV/RTV): effects on unbound methadone and alpha1 acid-glycoprotein (AAG). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001). Abstract A-492.
   Google Scholar
• CANTILENA L, MCCREA J, BLAZES D etal.: Lack of a pharmacokinetic interaction between indinavir and methadone. Clin Pharmacol Ther. (1999) 65(135):Abstract PI-74.
   Google Scholar
• MCCANCE-KATZ EF, FARBER S, SELWYN PA, OCONNOR A: Decrease in methodone levels with nelfinavir mesylate [letter]. Am. J. Psychiat. (2000) 157(3):481.
   PubMed Web of Science ®Google Scholar
• HSYU PH, LILLIBRIDGE JH, MAROLDO L, WEISS WR, KERR BM: Pharmacokinetic (PK) and pharmacodynamic (PD) in teractions between nelfinavir and methadone. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2000). Abstract 87.
   Google Scholar
• SMITH PF, BOOKER BM, DIFRANCESCO R etal.: Effect of methadone or LAAM on the pharmacokinetics of nelfinavir and M8. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001). Abstract A-491.
   Google Scholar
• AGENERASE [package insert]. GlaxoSmithKline, Research Triangle Park, NC, USA (1999).
   Google Scholar
• BART PA, RIZZARDI P, GALLANT S etal.: Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther. Drug Monit. (2001) 23(5):553-555.
   PubMed Web of Science ®Google Scholar
• CLARKE S, MULCAHY F, BERGIN C etal.: Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir/ritonavir. Clin. Infect. Dis. (2002) 34:1143-1145.
   PubMed Web of Science ®Google Scholar
• REYATAZ [package insert]. Bristol-Myers Squibb, Princeton, NJ, USA.
   Google Scholar
• PERLOFF ES, DUAN SX, SKOLNIK PR, GREENBLATT DJ, VON MOLTKE LL: Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism invitro. Drug Metab. Dispos. (2005) 33:764-770.
   PubMed Web of Science ®Google Scholar
• FRIEDLAND G, ANDREWS L, SCHREIBMAN T etal.: Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS (2005) 19(15):1635-1641.
   PubMed Web of Science ®Google Scholar
• TIPRANAVIR [package insert]. Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA (2005).
   Google Scholar
• JOHNSON RE, JAFFE JH, FUDALA PJ: A controlled trial of buprenorphine treatment for opiate dependence. JAMA (1992) 267:2750-2755.
   PubMed Web of Science ®Google Scholar
• LING W, CHARUVASTRA C, COLLINSJF etal.: Bu prenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction (1998) 93:475-486.
   PubMed Web of Science ®Google Scholar
• JOHNSON RE, CHUTUAPE M, STRAIN EC, WALSH SL, STITZER ML, BIGELOW GE: A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. (2000) 343:1290-1297.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI K, YAMAMOTO T, CHIBAK etal.: Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab. Dispos. (1998) 26:818-821.
   PubMed Web of Science ®Google Scholar
• MCCANCE-KATZ EF, PADE P, FRIEDLAND G, MORSE G, MOODYD, RAINEY P: Efavirenz decreases buprenorphine exposure, but is not associated with opiate withdrawal in opioid-dependent individuals. 12th conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005). Abstract 653.
   Google Scholar
• PADE P, EXHEM-WILLIAMS C, HELLEW L etal.: Buprenorphine does not alter efavirenz pharmacokinetics [abstract 101]. In: Program and abstracts of the 66th Annual Scientific Meeting of the College on Problems of Drug Dependence (San Juan, Puerto Rico). Philadelphia: College on Problems of Drug Dependence (2004):16.
   Google Scholar
• MCCANCE-KATZ E: Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin. Infect. Dis. (2005) 41(Suppl. 1):S89-S95.
   PubMed Web of Science ®Google Scholar
• BRUCE RD, ALTICE FL: Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS (2006) 20(5):783-784.
   PubMed Web of Science ®Google Scholar
• ORLAAM[package insert]. Roxane Pharmaceuticals, Columbus, Ohio, USA (2002).
   Google Scholar
• MCCANCE-KATZ EF, RAINEY PM, SMITH P etal.: Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am. J. Addict. (2004) 13(2):163-180.
   PubMed Web of Science ®Google Scholar
• CLARKE SM, MULCAHY F: Antiretroviral therapy for drug users. Int. J. STD AIDS (2000) 11(10):627-631.
   PubMed Web of Science ®Google Scholar
• GROSS R, BILKER WB, FRIEDMANHM, COYNE JC, STROM BL: Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS (2002) 16(13):1835-1837.
   PubMed Web of Science ®Google Scholar

Websites

• http://www.atforum.com/SiteRoot/pages/addiction_resources/Drug_Interactions.pdf LEAVITT S: Methadone-Drug Interactions 3rd Edition. Addiction Treatment Forum (2005).
   Google Scholar
• http://www.fuzeon.com/common/fpi.pdf Product information. T-20 (fuzeon).
   Google Scholar
• http://www.tthhivclinic.com Antiretroviralmethadone interactions. St. Michaels Hospital & Alice Tseng, PharmD, Toronto General Hospital (2005).
   Google Scholar
• http://www.hiv-druginteractions.org Liverpool HIV Pharmacology Group. HIV drug interactions website.
   Google Scholar